|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Irbesartan#Drug Interactions]] |
| {{Irbesartan}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Drug Interactions==
| |
| | |
| No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with [[hydrochlorothiazide]], [[digoxin]], [[warfarin]], and [[nifedipine]].
| |
| | |
| In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors [[sulphenazole]], [[tolbutamide]] and [[nifedipine]]. However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of [[warfarin]] were negligible. Based on in vitrodata, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.
| |
| | |
| In separate studies of patients receiving maintenance doses of [[warfarin]], [[hydrochlorothiazide]], or [[digoxin]], irbesartan administration for 7 days had no effect on the pharmacodynamics of [[warfarin]] prothrombin time) or pharmacokinetics of [[digoxin]]. The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or [[hydrochlorothiazide]].
| |
| | |
| Concomitant use of potassium-sparing [[diuretics]], potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.
| |
| | |
| Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
| |
| | |
| In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including irbesartan, may result in deterioration of [[renal function]], including possible [[acute renal failure]]. These effects are usually reversible. Monitor renal function periodically in patients receiving irbesartan and NSAID therapy.
| |
| | |
| The antihypertensive effect of [[angiotensin]] II receptor antagonists, including irbesartan, may be attenuated by NSAIDs including selective COX-2 inhibitors.
| |
| | |
| Dual Blockade of the [[Renin-Angiotensin System ]](RAS)
| |
| | |
| Dual blockade of the RAS with angiotensin-receptor blockers, ACE inhibitors, or [[aliskiren]] is associated with increased risks of [[hypotension]], [[hyperkalemia]], and changes in renal function (including acute renal failure) compared to monotherapy. Closely monitor blood pressure, renal function, and electrolytes in patients on AVAPRO and other agents that affect the RAS.
| |
| | |
| Do not coadminister [[aliskiren]] with AVAPRO in patients with diabetes. Avoid use of aliskiren with AVAPRO in patients with renal impairment (GFR <60 mL/min).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = AVAPRO (IRBESARTAN) TABLET [SANOFI-AVENTIS U.S. LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7885b2a8-be4e-48ab-8113-4e6ab791eb98 | publisher = | date = | accessdate = 20 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist}}
| |
| | |
| {{Angiotensin II receptor antagonists}}
| |
| | |
| [[Category:Angiotensin II receptor antagonists]]
| |
| [[Category:Sanofi]]
| |
| [[Category:Bristol-Myers Squibb]]
| |
| [[Category:Tetrazoles]]
| |
| [[Category:Biphenyls]]
| |
| [[Category:Lactams]]
| |
| [[Category:Spiro compounds]]
| |
| [[Category:Nitrogen heterocycles]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |